CompletedPhase 3Phase 4ACTRN12605000308695
Perioperative ischaemic evaluation trial
The effect of perioperative metoprolol on cardiac morbidity and mortality in patients presenting for non-cardiac surgery
Sponsor
MediClin Pty Ltd
Enrollment
10,000 participants
Start Date
Jan 31, 2003
Study Type
Interventional
Conditions
Summary
Patients with or at risk of ischaemic heart disease, who are having moderate or high risk non-cardiac surgery will be randomized to receive metoprolol CR or placebo for 30 days perioperatively. Outcomes include cardiac morbidity and mortality and safety endpoints.
Eligibility
Sex: Both males and femalesMin Age: 45 Yearss
Inclusion Criteria1
- With or at risk of ischaemic heart disease. Having moderatie or high risk non-cardiac surgery.
Exclusion Criteria1
- Bradycardia or heart block, bronchospasm, recent CABG surgery, beta-blockers or verapamil.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Metoprolol CR 200 mg daily for 30 days.
Metoprolol CR 200 mg daily for 30 days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000308695